Pharmacokinetics of dienogest as a single drug or in combination with estradiol valerate or ethinylestradiol

Drugs of Today

Volumn 35, Issue SUPPL. C, 1999, Pages 27-39

  Zimmermann, H ^a   Duvauchelle, T ^b   Gualano, V ^c   Kaufmann, G ^a   Bervoas Martin, S ^d   Breitbarth, H ^a   Mathieu, M ^d   Mellinger, U ^a   Ntsikoussalabongui, B ^c   Oettel, M ^a   Thebault, J J ^b  

^a BAYER PHARMA AG   (Germany)

^b Aster   (France)

^c Cephac ^*  (France)

^d Laboratoire Innothera   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIENOGEST; DIENOGEST PLUS ETHINYLESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; ETHINYLESTRADIOL; KLIMODIEN; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; ENDOMETRIOSIS; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; REVIEW;

EID: 0032782362     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Oettel, M., Bervoas-Martin, B., Eiger, W. et al. A 19-norprogestin without 17α-ethinyl group. I: DNG from a pharmacokinetic point of view. Drugs of Today 1995, 31: 499-516.
2. Oettel, M., Carol, W., Elger, W. et al. A 19-norprogestin without 17α-ethinyl group. II: DNG from a pharmacodynamic point of view. Drugs of Today 1995, 31: 517-36.
3. Oettel, M., Elger, W., Ernst, M. et al. Experimentelle Endokrinpharmakologie von Dienogest. In: Dienogest. Präklinik und Klinik eines Gestagens. Teichmann, A.T. (Ed.). W. de Gruyter: Berlin 2. Auflage 1995, 11-21.
4. Oettel, M., Breitbarth, H., Elger, W. et al. The pharmacological profile of dienogest. The Eur J Contraception Reproductive Health Care 1998, 3: 1-12.
5. Foster, R.H., Wilde, M.I. Dienogest. Drugs 1998, 56: 825-33.
6. Hobe, G., Hillesheim, H.G., Schön, R. et al. Zur Pharmakokinetik und Biotransformation von Dienogest bei verschiedenen Tierspezies. In: Dienogest. Präklinik und Klinik eines Gestagens. Teichmann, A.T. (Ed.), W. de Gruyter: Berlin 2. Auflage 1995, 33-49.
7. Juchem, M., Schaffrath, M., Pollow, K., Hoffmann, G., Kaufmann, G. Dienogest: Bindungsstudien an verschiedenen Rezeptor- und Serumproteinen. In: Dienogest. Praklinik und Klinik eines Gestagens. Teichmann, A.T. (Ed.). W. de Gruyter: Berlin 2. Auflage 1995, 119-33.
8. Hobe, G., Hillesheim, H.G., Küntzel, B., Klinger, G. Studies on non-protein bound dienogest in plasma of different species. Naunyn-Schmiedeberg's Arch Pharmacol Suppl 1993, 347: R44
9. 3H-STS 557 (Dienogest) in Hepatocyte Cultures and Microsomes of Rat, Dog, Monkey and Human. Jenapharm Company documentation 1993.
10. Hobe, G, Hillesheim, H.G., Schumann, W., Rifter, P., Claullen, C. Studies on pharmacokinetics of STS 557 in animal species and man. Exper Endocrinol 1983, 81: 158-67.
11. Hobe G., Schön, R., Wehrberger, K., Schade, W., Rifter, P., Hillesheim, H.G. Studies on the biotransformation of the progestagen dienogest in the rabbit. Exp Clin Endocrinol 1989, 94: 203-10.
12. Schubert, K., Hobe, G., Kaufmann, G., Schumann, G., Wehrberger, K., Hörhold, C. Studies on biotransformation of STS 557. Exper Clin Endocrinol 1983, 81: 168-74.
13. Wehrberger, K., Ritter, P., Hillesheim, H.G., Hobe, G. Metabolite patterns obtained by HPLC of the new progestagen dienogest. Proc Symp on Analysis of Steroids (Szeged, Hungary 1984) 511-8.
14. Bervoas-Martin, S., Bromet, N., Caizergues, P. et al. Detection and Identification of STS 557 Metabolites in Human (Female) Urine by Liquid Chromatography Coupled to Mass Spectrometry. Jenapharm Company documentation 1994.
15. Hobe, G., Oeftel, M., Klinger, G., Köhler, G., Hörhold, C. The new progestagen dienogest: Effects and metabolism. Proc 4th Symp Analysis of Steroids. Görög, S. (Ed.). (Pecs 1990) 371-7.
16. Schubert, K., Hobe, G. Biotransformation of STS 557 in Man. Jenapharm Company documentation 1979.
17. Chemnitius, K.H., Claußen, C. Report: Evaluation of the Pharmacokinetics of STS 557 in Man. Jenapharm Company documentation 1979.
18. Hobe, G. Final Report on WHO-Project 81096: Metabolism of STS 557 in Women. Jenapharm Company documentation 1983.
19. Fotherby, K. Pharmacokinetics and metabolism of progestins in humans. In: Pharmacology of the Contraceptive Steroids. Goldzieher, J.W. (Ed.). Raven Press: New York 1993, 99-126.
20. Hoffmann, A., Reimann, I.R., Nassr, N., Hobe, G., Mellinger, U., Kuhl, H. Pharmakokinetik von Dienogest als Monopräparat und in Kombination mit Ethinylestradiol. In: Dienogest. Präklinik und Klinik eines Gestagens. Teichmann, A.T. (Ed.). W. de Gruyter: Berlin 2. Auflage 1995, 95-104.
21. Strauch, G., Perles, P. Open, Randomized (Latin Square Design) Trial to Determine Linearity of Dienogest Pharmacokinetics in 12 Healthy Female Volunteers, Treated with 1, 2, 4 and 8 mg of Dienogest, Administered Successively as a Single Dose After Wash-out Corresponding to Duration of the Menstrual Cycle (Dienogest Tablets Containing 1 mg). Jenapharm Company documentation 1994.
22. Böcker, R., Kleingeist, B. Der Einfluß von Dienogest auf das humane Cytochrom P-450 Enzymsystem in vitro. In: Dienogest. Präklinik und Klinik eines Gestagens. Teichmann, A.T. (Ed.). W. de Gruyter: Berlin 2. Auflage 1995, 141-7.
23. Balogh, A., Liewald, T., Liewald, S. et al. Zum Einfluß eines neuen Gestagens -Dienogest und seiner Kombination mit Ethinylestradiol auf die Aktivitat von Biotransformationsreaktionen. Zentralblaft Gynakologie 1990, 112: 735-46.
24. Hieu, D.C., Reddersen, G., Wehrberger, K., Hobe, G. Radioimmunoassay of the progestagen dienogest using different methods of plasma sample preparation. Pharmazie 1986, 41: 711-4.
25. Shah, V.P., Midha, K.M., Dighe, S. et al. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies. J Pharm Sci 1992, 81: 309-12.
26. Kuhnz, W., Al-Yacoub, G., Fuhrmeister, A. Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation. Contraception 1992, 46: 455-69.
27. Kuhnz, W., Staks, T., Jütting, G. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: Serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. Contraception 1994, 50: 563-79.
28. Kuhnz, W., Baumann, A., Staks, T., Dibbelt, L., Knuppen, R., Jütting, G. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: Serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. Contraception 1993, 48: 303-22.
29. Fotherby, K. Levonorgestrel. Clinical Pharmacokinetics Clin Pharmacokinet 1995, 28: 203-15.
30. Kuhnz, W. Pharmacokinetics of the contraceptive steroids levonorgestrel and gestodene after single and multiple oral administration to women. Am J Obstet Gynecol 1990, 163: 2120-27.
31. Jung-Hoffmann, C., Fitzner, M., Kuhl, H. Oral contraceptives containing 20 or 30 μg ethinylestradiol and 150 μg desogestrel: Pharmacokinetics and pharmacodynamic parameters. Horm Res 1991, 36: 238-46.
32. Kuhl, H. Pharmacokinetics of oestrogens and progestogens. Maturitas 1990, 12: 171-97.
33. Kuhl, H. Comparative pharmacology of newer progestogens. Drugs 1996, 51: 188-215.
34. Kuhnz, W., Al-Yacoub, G., Fuhrmeister, A. Pharmacokinetics of levonorgestrel in 12 women who received a single oral dose of 0.15 mg levonorgestrel and, after a wash-out phase, the same dose during one treatment cycle. Contraception 1992, 46: 443-54.
35. Kuhnz, W., Gansau, C., Fuhrmeister, A. Pharmacokinetics of gestodene in 12 women who received a single oral dose of 0.075 mg gestodene and, after a wash-out phase, the same dose during one treatment cycle. Contraception 1992, 46: 29-40.